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Abstract Osteoarthritis (OA) is one of the most common
causes of musculoskeletal disability in the world. Traditional-
ly, it has been thought that obesity contributes to the develop-
ment and progression of OA by increased mechanical load of
the joint structures. Nevertheless, studies have shown that ad-
ipose tissue-derived cytokines (adipocytokines) are a possible
link between obesity and OA. Furthermore, according to re-
cent findings, not only articular cartilage may be the main
target of these cytokines but also the synovial membrane,
subchondral bone and infrapatellar fat pad may be
encompassed in the process of degradation. This review pre-
sents the most recent reports on the contribution of
adipocytokines to the knee joint cartilage degradation, osteo-
phyte formation, infrapatellar fat pad alterations and synovitis.
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Introduction
Osteoarthritis (OA) is a progressive and disabling disease, one
of the most commonmusculoskeletal disorders. OA originates
as a result of the action of risk factors such as genetics, old age,
female gender, obesity and injury [1, 2]. The disease is char-
acterized by the progressive loss of articular cartilage with
concomitant joint space narrowing, osteophyte formation,
subchondral sclerosis and synovitis. An important feature of
OA is the extension of the spectrum of damage from the ar-
ticular cartilage to the entire joint structures [3]. The patholog-
ical processes taking place in cartilage, bone and synovial
membrane result in pain, loss of function and in consequence
disability. It has been estimated that in the USA symptomatic
knee OA occurs in 10 % of men and 13 % of women aged
60 years or older and it is likely to increase because of the
aging of the population and the increasing numbers of obese
persons [4].
Although numerous risk factors contribute to the process of
joint degradation, over the past ten years the association of
obesity and OA has been well documented [5, 6]. One of the
most important problems addressed by this intensive research
until now is whether the impact of obesity on the development
of OA is solely caused by an increased mechanical load in
obese individuals, or rather, whether this influence is due to
specific biochemical processes activated by, or directly related
to the endocrine function of adipose tissue [7, 8]. The white
adipose tissue (WAT) has the potential to produce various
substances that have some functional similarity to classic en-
docrine hormones, although they differ from them in many
aspects. Those substances were named adipocytokines, and
in line with the latter hypothesis, recent investigations reveal
a role played by adipocytokines in the degradation of carti-
lage, synovium and bone [9, 10].
This review summarizes the most recent reports on the role
of adipocytokines in the pathogenesis of knee joint OA.
Adipocytokines
Adipocytokines are bioactive proteins secreted mainly by
WAT, first identified in the early 1990s. So far, the role of
adipocytokines in the metabolism of bone tissue and its con-
tribution to the differentiation of bone marrow cells to
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osteoblasts [11, 12], as well as an important role in the path-
ogenesis of metabolic syndrome have been demonstrated [13,
14]. Some adipocytokines might also play a direct role in
maintaining an inflammatory state in the joints of obese indi-
viduals (the so-called low-grade inflammatory state) [15].
These proteins have been detected in synovial fluid (SF) and
the plasma of patients with OA [16–18]. A putative source of
adipocytokine secretion in the region of the knee joint is the
infrapatellar fat pad (IPFP) [19, 20]. In addition, recent find-
ings indicate that deteriorated articular cartilage is another
source of adipocytokines within the joint [21]. Furthermore,
adipocytokines originating from the adipose tissue, which acts
as an endocrine organ, can directly initiate the abnormalities in
structure and function of articular cartilage in obese individ-
uals [14]. This Bexternal^ action is then added to the action of
adipocytokines produced inside the joint, which further dete-
riorates the condit ion of the joint . Of numerous
adipocytokines, the best characterized are leptin, resistin,
adiponectin, vaspin, omentin, visfatin and adipsin [22].
Leptin
From all adipocytokines, leptin was discovered first and is
best characterized [23]. It is a polypeptide of 146 amino acids,
and Mr 16 kDa, encoded by the obese gene (ob) localized on
chromosome 7q31.3. Leptin is a multi-functional protein. It
has s metabolic, neuroendocrine, and immunomodulatory ef-
fects. The activity of leptin is mediated by the Ob receptor
(ObR) encoded by the diabetes gene (db). Leptin is produced
mainly in the adipocytes of subcutaneous WAT and in the
glandular cells of the stomach, in the liver and in the endothe-
lial cells of the mammary gland [24–26]. The concentration of
leptin fluctuates the highest being during the night and the
lowest during the day. In healthy individuals, the plasma con-
centration of leptin ranges from 5 to 15 μg/L [27]. The con-
centration of leptin is higher in women, which is connected
with larger stores of subcutaneous adipose tissue [28]. There
are significantly higher ratios of plasma leptin concentrations
to fat mass in girls than boys at the late stage of puberty.
However, there are no significant differences in leptin concen-
trations in prepubertal and early pubertal children [29].
Leptin is secreted in a free form or is bound to its receptor.
The bound form regulates mainly the energy balance. Leptin
plays the role of a Bguardian^ of adipose tissue stores in the
body. As a result of direct action on the central nervous sys-
tem, it restrains hunger evoking the feeling of satiety and
regulating thermogenesis as well as increasing energy expen-
diture [30]. Acting similarly to insulin, leptin lowers blood
glucose level [24, 30]. It was also suggested that leptin acts
as an acute phase protein having pro-inflammatory action
through T-lymphocyte stimulation resulting in the liberation
of cytokines such as interleukins (ILs) and tumor necrosis
factor-α (TNF-α) and increasing the activation level of NK
cells, macrophages and neutrophils [31].
Resistin
Resistin is a polypeptide of 105 amino acids and Mr 12 kDa
encoded by the RSTN gene localized on chromosome 19p13.3
[32]. It is produced mainly in WAT and also in bone marrow,
the spleen, lungs, placentas and the pancreas. Resistin takes
part in adipogenesis, insulin resistance and inflammatory pro-
cesses and exhibits a positive correlation with the occurrence
of obesity, insulin resistance, and chronic inflammation [33].
It induces the secretion of pro-inflammatory cytokines such as
IL-1, IL-6, IL-12 and TNF-α in a NF-κB-mediated fashion
[34, 35]. Resistin elevates the concentrations of TNFα, IL-1β
and IL-6 in plasma and increases catabolism and proteoglycan
levels after experimental joint injury [36]. It has also been
demonstrated that resistin up-regulates the intercellular adhe-
sion molecule-1 (ICAM1), vascular cell-adhesion molecule-1
(VCAM1) and chemokine ligand 2 (CCL2) [37].
Adiponectin
Adiponectin is a polypeptide of 244 amino acids, but it spon-
taneously polymerizes to form trimers, hexamers and
dodecamers. Adiponectin is encoded by the ADPOQ gene,
which is localized on chromosome 3q27. It is produced by
the majority of WAT cells and to a lesser extent by visceral
adipose tissue (VAT). It takes part in the metabolism of carbo-
hydrates and lipids, and plays an important role in thermoreg-
ulation by combusting ectopic adipose tissue. It also increases
the insulin sensitivity of muscle and liver tissues. The plasma
concentration of adiponectin reveals sexual dimorphism with
females having higher levels than males. It ranges from 500 to
30,000 μg/L [24] and increases in degenerative joint disease
and rheumatoid arthritis [15]. Adiponectin binds to a number
of G protein-coupled receptors and the expression level of
these receptors is elevated in articular cartilage, which is af-
fected by degeneration [38]. The role of adiponectin played in
the inflammatory process is not completely elucidated. It was
suggested that it affects IL-1β, IL-6, MMP-13 [39], MMP-1,
MMP-3, NO [38], and MMP-9 secretion [40].
Visfatin
Visfatin is a protein of Mr 52 kDa, a nicotinamide
phosphoribosyltransferase enzyme, which acts as a dimer.
Visfatin, first detected in skeletal muscles, liver and bone mar-
row, is encoded by the PBEF1 gene [41]. It is secreted by
visceral fat tissue [42] and is implicated in a number of
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conditions, such as aging, atherosclerosis, pathogenesis of
type 2 diabetes and rheumatoid arthritis [43]. Its role in met-
abolic processes is still controversial, but it has been reported
that the properties of visfatin are similar to insulin. It has been
suggested that the levels of visfatin are higher in obese [44,
45] and in OA patients [46]. In an experimental study, it has
been found that visfatin level could be down-regulated by the
overexpression of miR34a, which binds directly to the 3′UTR
of visfatin mRNA. In obese mice, adipocytokine level corre-
lated inversely with the elevated levels of miR-34a [47].
Other adipocytokines
Omentin is also known as an intestinal lactoferrin receptor. It
is a 313-amino-acid protein encoded by the ITLN1 gene,
which is secreted by the visceral stromal vascular cells of the
abdominal adipose tissue (but not by adipocytes), and is also
synthesized in small intestine, lungs and heart muscles [48,
49]. Omentin causes vasodilation and attenuates C-reactive
protein-induced angiogenesis via the nuclear factor kappa B
signaling pathway. Although its function is not completely
elucidated, it is known that it potentiates the effect of insulin
on glucose metabolism [48] and its gene expression is altered
in inflammation and in obese patients [50].
Vaspin (visceral adipose tissue-derived serine protease in-
hibitor) is a protein of 395 amino acids, with aMr of 45.2 kDa,
encoded by the Serpina12 gene. Its expression in adipose
tissue is regulated in a fat depot-specific manner and is asso-
ciated with obesity, insulin resistance, and abnormal glucose
metabolism. It is produced by visceral tissue adipocytes,
shares about 40 % sequence homology with α1-antitrypsin,
and its secretion alters glucose tolerance and insulin sensitivity
[51]. These findings indicate that vaspin exerts an insulin-
sensitizing effect targeted toward WAT in states of obesity.
Vaspin structure is similar to adiponectin and it acts as an
anti-inflammatory agent, suppressing TNFα, leptin and
resistin secretion [52, 53].
Adipsin (complement factor D) is a protein encoded by the
CFD gene. It affects both the lipid and glucose metabolism. It
is a serine protease that stimulates glucose transport for tri-
glyceride accumulation in fats cells and inhibits lipolysis. It
has been initially indicated that adipsin level correlates with
obesity, dyslipidemia, insulin resistance and cardiovascular
diseases [54].
Adipocytokines in cartilage degradation
A crucial feature of OA is the progressive loss of articular
cartilage. Cartilage degradation is a result of the increased
expression of genes encoding proteolytic enzymes such as
metalloproteinases (MMPs) and aggrecanases (AGGs), as
well as inflammatory cytokines, nitric oxide (NO) and prosta-
glandins (PGEs). The secretion of enzymes involved in the
degradation of cartilage accompanied by insufficient cartilage
repair result in the breakdown of homeostasis and a shift to-
ward catabolic processes. Adipocytokines acting in an auto-
crine or paracrine manner stimulate chondrocytes in a dual
way. One of the first studies on the impact of leptin on carti-
lage cells revealed that this peptide increases the anabolic
activity of chondrocytes by inducing IGF-1 and TGF-β ex-
pression at both mRNA and protein levels [55]. However,
further studies have shown contradictory results. Leptin was
reported to increase MMP-2, MMP-9, cathepsin D and type II
collagen expression in vivo, at both mRNA and protein levels.
This peptide also up-regulated ADAMTS-4 and ADAMTS-5
expression, causing proteoglycan depletion from the articular
cartilage of rats [46]. The latest data suggest that leptin induces
ADAMTS-4, ADAMTS-5, and ADAMTS-9 gene expression
by mitogen-activated protein kinases and NF-ĸB signaling
pathways in human chondrocytes, which results in the subse-
quent increase of inflammatory processes [56]. Vuolteenaho
et al. [57] showed that leptin enhanced NO synthesis and
PGE2, IL-6 and IL-8 secretion in OA cartilage. Berry et al.
[58] found that the presence of the soluble leptin receptor
(sOB-Rb) is associated with reduced cartilage synthesis and
increased levels of the tissue degradation marker (N-terminal
type IIA procollagen propeptide, PIIANP).
Similarly, adiponectin has both a pro- and anti-
inflammatory effect on tissues. Acting in vitro, this peptide
induced iNOS activity and IL-6, MMP-3, MMP-9 and
MCP-1 (monocyte chemattractant protein-1) expression
[40]. In the study of Francin et al. [59] the adiponectin tran-
script level was significantly correlated with those encoding
prostaglandin E2 and MMP-13. By contrast, Chen et al. [60]
showed the protective effect of adiponectin on articular carti-
lage by up-regulating the tissue metallo-proteinase inhibitor
(TIMP-2) and decreasing IL-1β-mediated MMP-13 expres-
sion. In patients with severe OA, higher plasma adiponectin
levels were found and their chondrocytes expressed both
adiponectin receptors (AdipoR1 and AdipoR2) and AdipoR1
was mainly expressed in the superficial layers of OA cartilage
[40]. Visfatin had a catabolic effect on articular cartilage. Pro-
duced by OA chondrocytes it increased MMP-3, MMP-13 as
well as ADAMTS-4 and ADAMTS-5 activity in a mouse
model [61]. Yammani and Loeser [62] demonstrated that, in
human cartilage, visfatin inhibited IGF-1 and led to IGF-1-
mediated proteoglycan synthesis. Moreover, Hong et al. [63]
suggested that visfatin could alter the expression, of
chondrogenic factors such as the sex-determining region Y-
box 9 (SOX-9) and type II collagen. In OA patients visfatin SF
level positively correlated with the degradation markers of
collagen, (CTX-II) and aggrecans (AGG1, AGG2) [64]. Re-
cent studies show that most articular visfatin derives from
synovium, and the activity of visfatin is involved in
International Orthopaedics (SICOT) (2015) 39:1211–1217 1213
chondrocyte and osteoblast activation, so targeting this enzy-
matic activity to disrupt joint tissue interactions may be novel
in OA therapy [65].
Adipocytokines in osteophyte formation
Osteophyte formation is one of the hallmarks of OA. It has
been suggested that osteophytes result from the abnormal
healing response of subchondral trabeculae, or from the blood
vessels penetration into the degrading cartilage [66]. It has
been also shown that in OA the patient’s osteophytes express
TGF-β, which induces osteophyte formation in an experimen-
tal model [67, 68]. Thomas et al. [11] suggested that the action
of leptin on bone tissue may be a result of bone marrow stro-
mal cell stimulation and enhanced cell differentiation into os-
teoblasts with limited differentiation into adipocytes. In the
study of Berry et al. [58], high leptin levels were associated
with increased bone formation markers, such as osteocalcin
and PINP (N-terminal type I procollagen propeptide). How-
ever, no associations were found between adipocytokine level
and bone resorption markers (CTX-I, NTX-I and ICTP). An-
other study revealed that in subchondral bone osteoblasts of
OA patients leptin expression levels were about fivefold than
in normal osteoblasts and protein level was approximately
twofold in OA cells compared to normal [69]. In the magnetic
resonance imaging (MRI)-assessed knee joints, leptin levels
were also strongly associated with osteophyte formation.
Higher adipocytokine levels were found among women with
larger osteophytes (>10 mm) than in those with no or smaller
osteophytes (<10 mm) [70]. Visfatin has been also found to
influence osteoblasts proliferation and type II collagen pro-
duction [71].
Adipocytokines secretion by infrapatellar fat pad
The infrapatellar fat pad (IPFP), situated within the knee joint
capsule, contains in addition to adipocytes, macrophages,
lymphocytes and granulocytes, and may serve as a local
source of adipose tissue-derived cytokines [72]. Several stud-
ies demonstrated that IPFP-derived adipocytokines could
have a direct impact on articular cartilage. When the
subcutaneous fat tissue (SCFT) and fat pad tissue
(FPT)-derived cells were compared, IPFP adipocytes
showed a twofold increase in IL-6 gene expression
and in IL-6 release. Interestingly, leptin secretion was
40 % lower and adiponectin was increased by 70 %
in IPFP cells compared with the subcutaneous adipose
tissue [73]. Moreover, it was demonstrated that the cul-
ture media from OA patients’ IPFP adipocytes induced
MMP13 and MMP1 expression in articular chondrocytes
and that the leptin level positively correlated with the
expression of both MMPs and cartilage collagen de-
struction [20]. The end-stage OA patients’ fat pad cells
also showed an increased expression of inflammatory
cytokines and down-regulation of anabolic peptides,
such as VCAM1 (vascular cell adhesion molecule-1),
CTGF (connective tissue growth factor) and CD44
(cluster of differentiation) [74].
Adipocytokines and synovitis
Changes of the synovial membrane in the course of OA in-
clude synovial hyperthrophy and hyperplasia, sometimes ac-
companied by tissue thickening. It is believed that a low-grade
inflammatory state induced by synovial membrane may en-
hance IL-1β and TNF-α expression, which contributes to car-
tilage degradation [75]. Adipocytokines can be detected local-
ly both in the synovium and synovial fluid (SF) of OA indi-
viduals. Nevertheless, the exact role of these peptides in in-
ducing synovitis is unknown. Several studies provide infor-
mation regarding this issue. De Boer et al. [9] have found that
serum leptin, resistin and adiponectin levels were significantly
correlated with the inflammation of local synovial tissue, but
no association was found between adipocytokine level and
cartilage damage markers as well as GAGs content. However,
Hao et al. [76] demonstrated that the SF adiponectin level
correlated with aggrecan depletion markers (AGG1 and
AGG2), but not with the type II collagen degradation marker
(CTX-II). By contrast, Honsawek et al. [77] found that SF
adiponectin level was lower in severe OA and negatively cor-
related with OA grade and BMI. Correspondingly, the SF/
plasma leptin ratio has been found to be significantly lower
in the end-stage OA compared to early stages of the disease
[78]. More recently, a study by Bas et al. [79] revealed that
low SF adiponectin level and high SF leptin level were asso-
ciated with worse pre-operative pain scores in the knees of OA
patients.
Conclusions
Adipocytokines participate in numerous metabolic and in-
flammatory processes in the body. The currently published
data suggest their pivotal role in the course of OA. It has been
shown that in the knee joint the source of cytokines is not only
systemic but also local, since cartilage, synovium or
infrapatellar fat could be the source itself. Therefore, the role
of obesity as a risk factor and cause of OA may not be limited
to biomechanical loading, but also associated with adipose
tissue secretory activity. Given the epidemic of obesity and
OA, it is clear that these two conditions cannot be ignored
and a modifiable risk factor, such as being overweight, should
be targeted in order to reduce knee OA incidence.
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